The article has been translated automatically. Translated in:
The Role of Patents in the Pharmaceutical Industry
Pharmaceutical patents are a cornerstone of the innovation ecosystem, providing essential incentives for companies to invest in the costly and time-consuming process of drug development. The average pharmaceutical product takes over a decade and an estimated $2.6 billion to bring to market, from initial discovery to regulatory approval. Without the protection of patents, it would be difficult for companies to recover these investments, as competitors could easily produce and sell generic versions of a newly developed drug at a fraction of the cost.
Patents grant a temporary monopoly, usually lasting 20 years from the filing date, during which the patent holder has the exclusive right to produce, market, and sell the drug. This exclusivity allows the company to set prices that reflect both the R&D expenses and the risk of failure (given that most drug candidates do not make it through clinical trials). The resulting profits fund future innovation and compensate for the high attrition rate in pharmaceutical research.
The patent system, while essential to pharmaceutical companies, is not without its critics. Critics argue that patents can lead to inflated drug prices, making essential medicines inaccessible to many, particularly in LMICs. High drug prices, such as those seen with HIV/AIDS treatments in the 1990s or more recently with cancer therapies and biologic drugs, underscore the tension between protecting innovation and ensuring public health.
Copyright vs. Patents: Understanding Intellectual Property Rights in Pharma
While both copyright and patents are forms of intellectual property (IP) protection, they serve distinct purposes, especially in the pharmaceutical industry. Copyright primarily protects creative works, such as books, films, and software, by granting the creator exclusive rights to reproduce, distribute, and display the work. In contrast, patents protect inventions, including new drugs, manufacturing processes, and medical devices.
For pharmaceutical companies, patents are far more critical than copyrights. A new drug is typically the result of years of experimentation, testing, and development, making patent protection crucial for recouping the costs of innovation. Patents cover the composition of a drug, its method of use, and the manufacturing process. In some cases, secondary patents can be filed to extend market exclusivity, for example, by patenting a new formulation or delivery method for an existing drug.
The differences between patents and copyrights reflect the nature of pharmaceutical innovation, which is more about scientific discovery and less about creative expression. While copyrights may apply to clinical study reports, research publications, or marketing materials, patents protect the core innovation in drug development, safeguarding the molecule or treatment that holds therapeutic value.
The Role of Pharmaceutical Companies
The pharmaceutical industry is a highly complex and competitive environment, dominated by two major types of companies: large multinational corporations, often referred to as “Big Pharma,” and smaller biotechnology firms. Both rely heavily on patents to survive and thrive, although their approaches to innovation and IP protection can differ significantly.
- Big Pharma and Patent Strategies: Large pharmaceutical companies typically maintain vast patent portfolios to protect their discoveries and control market share. They invest heavily in R&D, with revenues often exceeding billions of dollars annually, and rely on patent protection to generate returns on this investment. Companies like Pfizer, Merck, and Johnson & Johnson are prime examples of Big Pharma firms that utilize patent protection to safeguard blockbuster drugs. – Products that generate annual sales of more than $1 billion. Big Pharma often uses patent thickets, which involve filing numerous patents around a single drug, to extend market exclusivity and block generic competition.
- Biotech Startups and Venture Capital: Smaller biotechnology companies also depend on patents, but for different reasons. For many startups, patents are essential for attracting venture capital funding. These companies often focus on early-stage research, such as developing novel drug targets or delivery systems, and then rely on partnerships or acquisitions by larger firms to bring their products to market. Without strong patent protection, biotech startups would struggle to secure the investment needed to develop new therapies, as potential investors would be concerned about the risk of imitation by competitors.
Both types of companies are critical to the pharmaceutical innovation ecosystem. Big Pharma has the resources to take drugs through the lengthy and costly regulatory approval process, while biotech firms often lead the way in early-stage research and development. Together, they form a symbiotic relationship that drives pharmaceutical innovation.
The Drug Development Process and Patent Timelines
The drug development process is notoriously lengthy, with several key stages that contribute to the overall cost and time required to bring a new drug to market. These stages include:
- Discovery and Preclinical Research: Researchers identify potential drug targets (such as proteins or genes involved in a disease) and conduct laboratory tests to evaluate their effects. This phase can take several years and is often the most uncertain, as many drug candidates fail to show promise in early testing.
- Clinical Trials (Phases I-III): Once a drug shows potential in preclinical research, it enters clinical trials, which involve testing the drug on humans. Clinical trials are divided into three phases (Each phase can last several years, and drugs may fail at any point):
- Phase I: Tests the drug’s safety in a small group of healthy volunteers.
- Phase II: Evaluates the drug’s efficacy in a larger group of patients with the target condition.
- Phase III: Conducts large-scale testing to confirm efficacy and monitor for side effects.
- Regulatory Review and Approval: After successful clinical trials, the drug is submitted to regulatory bodies (such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA)) for approval. This process can take additional years as regulators review the data for safety, efficacy, and manufacturing quality.
- Post-Approval and Marketing: Once approved, the drug enters the market, where it is typically protected by patents for the remainder of the 20-year period. However, due to the length of the development process, the patent clock starts ticking long before the drug reaches the market, leaving most drugs with only 7-12 years of effective market exclusivity.
During the post-approval period, companies often engage in marketing and may pursue secondary patents on different formulations, combinations, or uses of the drug to extend the period of exclusivity beyond the original patent’s expiration.
Patents as a Double-Edged Sword: Encouraging Innovation vs. Limiting Access
While patents are essential to incentivizing pharmaceutical innovation, they also create challenges in terms of global access to medicines. Patent-protected drugs are often priced out of reach for many in developing countries, where public health systems are underfunded and patients lack the ability to pay high prices for treatments. This disparity became particularly apparent during the HIV/AIDS crisis of the late 20th century when antiretroviral drugs were available in high-income countries but inaccessible to millions of patients in LMICs.
To address this issue, international agreements, such as the Doha Declaration on the TRIPS Agreement and Public Health (2001), have sought to provide some flexibility in patent enforcement, allowing countries to issue compulsory licenses in cases of public health emergencies. A compulsory license permits a government to authorize the production of a patented drug without the consent of the patent holder, usually in exchange for a fee. This mechanism has been used successfully to expand access to life-saving treatments in certain circumstances, but its application remains contentious, with many developed countries and pharmaceutical companies viewing it as an infringement on IP rights.
Moreover, the Covid-19 pandemic has brought renewed attention to the limitations of the patent system, particularly in terms of vaccine access. While patent protection incentivized the rapid development of Covid-19 vaccines, it has also raised concerns about unequal distribution, with high-income countries securing the bulk of early vaccine supplies, leaving many LMICs behind.
Italy before 1978 – Without Patents for Pharmaceutical Inventions
In Italy patent protection for pharmaceutical products became available only in 1978. At that time the Constitutional Court (20/03/1978 no. 20) pronounced the unconstitutionality of art. 14 of the R.D. 29/06/1939, no. 1127 (the law on industrial inventions) which prohibited the granting of patents to pharmaceutical inventions, on the ground of some “moral” justifications. The Supreme Court ruled in favor of eighteen pharmaceutical companies, all foreign, requesting the enforcement of foreign patents on medical products in Italy. But surprisingly in spite of this complete lack of any patent protection, Italy had developed a strong pharmaceutical industry: by the end of the 1970s it was the fifth world producer of pharmaceuticals and the seventh exporter [1].
Spending on pharmaceutical R&D in Italy rose from 123 billion lire in 1978 to 1,632 billion lire in 1992, rising from 7.78% of turnover to 11.99% [2]. New pharmaceutical products of Italian origin marketed between 1975 and 1989 made up 9.2% of the world total of 775, while those defined as “of substantial therapeutic innovation” increased from 1.25% of the world total in 1975-79 to 2.78% during 1980-84 and to 3.9% during the period 1985-89.
But strong evidence that concentration and patent protection go hand in hand comes from the Italian experience before and after the 1978 watershed. Before 1978 the Italian pharmaceutical industry was characterized by the presence of a large number of small and medium sized independent firms. After 1978, industry concentration proceeded rapidly: the total number of independent firms went from 464 in 1976 to 390 in 1980 and 335 in 1985. During the same period, no concentration of the productive activity took place in the pharmaceutical industry of the other large western countries. The Italian pharmaceutical industry, in the meanwhile, has lost market share at a constant pace both nationally and worldwide [3]. A conclusion may be drawn: patents in the health industry are likely to favour larger industrial structures. Concerning smaller markets than in the US it is much discussed whether the economic impact of patents in the life sciences and their role in stimulating innovation and attracting investment from the industry in medical R&D are susceptible to cause positive effects or not [4].
